BioCentury
ARTICLE | Finance

Analyst tracks

Biotech investor, banker and analyst personnel changes

July 15, 2013 7:00 AM UTC

Andrew Fein, who joined H.C. Wainwrightas a senior biotechnology analyst and managing director in May, initiated coverage of several companies, including cardiovascular company United Therapeutics Corp. (NASDAQ:UTHR), infectious disease play Synthetic Biologics Inc. (NYSE-M:SYN) and HCV and cystic fibrosis company Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Fein was a managing director at Chardan Capital Markets.

Ken Hitchner became president of Goldman Sachs in Asia Pacific Ex-Japan. He was global head of the healthcare banking group and global co-head of the technology, media and telecom group...